• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Department of Defense awards $2 million to spinal cord injury research

Department of Defense awards $2 million to spinal cord injury research

May 30, 2013
CenterWatch Staff

The Christopher & Dana Reeve Foundation and Capstone National Partners announced a $2 million grant from the Department of Defense (DOD) to further support the expansion of translational research to find treatments for individuals living with spinal cord injury, including servicemen and women.

"Spinal cord injuries can be devastating and this DOD award affords us the opportunity to test promising interventions in clinical trials and identify effective treatments for this country's war wounded and for spinal cord patients throughout the world," said Susan Howley, the Reeve Foundation's executive vice president for research.

The DOD awarded the two-year, peer-reviewed grant to the Reeve Foundation's North American Clinical Trials Network (NACTN), a consortium of university hospital neurosurgical and neurorehabilitation teams to bring promising therapies into clinical trials. Led by Dr. Robert G. Grossman, professor of neurosurgery at The Methodist Hospital Neurological Institute in Houston, NACTN gathers and documents patient medical information in a data registry to better understand the body's natural course of recovery after injury, uses standardized patient assessment protocols and develops new ones and conducts new trials of therapy for spinal cord injury.  

The funding will support a phase II/III efficacy trial of Riluzole, a neuroprotective drug that is the only FDA-approved drug used in the treatment of amyotrophic lateral sclerosis. Laboratory studies have shown it to be effective in limiting traumatic damage to the spinal cord.

NACTN, launched by the Reeve Foundation in 2004, originally had six centers in North America.  Since then, the network has expanded to 10 clinical sites, a data management center and a pharmacology center.  

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing